7 / 35
Notes:
Page 69
Volume 08
Clinical Pharmacology & Biopharmaceutics
ISSN: 2167-065X
Pharmacology 2019
World Heart Congress 2019
August 19-20, 2019
JOINT EVENT
conferenceseries
.com
August 19-20, 2019 Vienna, Austria
&
7
th
World Heart Congress
24
th
World Congress on
Pharmacology
Are oral arginine supplements effective in attenuating hypertension?
Sarah Martin
University of Saskatchewan, Canada
O
ral L-arginine supplements have been tried to lower blood pressure with conflicting results, with one of the
factors affecting the outcome is whether the subject is healthy or has hypertension. Arginine is a substrate
for at least four enzymes including nitric oxide synthase and arginase, but the impact of oral supplements on its
different metabolic pathways is not clear. We examined the effect of L-arginine and D-arginine, at two different
doses of 500 mg/kg/d (500) or 1000 mg/kg/d (1000) in drinking water administered for 4, 12 or 16 weeks to separate
groups of 9 week old male Sprague-Dawley (SD) rats or 5 week old male Zucker Diabetic Fatty (ZDF) rats. We
report the effects on the endothelial nitric oxide synthase (eNOS)/nitric oxide (NO) and the arginase/urea metabolic
pathways. L-arginine (500) increased eNOS expression in the aorta and the kidney and plasma nitrite levels, but
did not affect the mean arterial pressure (MAP) in the SD rats. L-arginine (500) also decreased arginase II in the
ileum. D-arginine also unexpectedly increased eNOS expression in the kidney and decreased arginase in the liver
and the ileum. Arginine (1000) also did not affect the MAP in the SD rats. On the other hand, L-arginine (1000)
attenuated the increase in MAP in the ZDF rats without affecting eNOS expression or nitrite levels. However, it did
not attenuate the increased arginase expression or urea levels in the ZDF rats as compared to Zucker lean rats. In
conclusion, two different doses and durations of oral arginine treatment did not affect the MAP in Sprague-Dawley
rats, but attenuated it in the ZDF rats. Thus, the blood pressure lowering effect of oral L-arginine should not be taken
for granted and their effects on the arginase and other metabolic pathways (results not shown) should be considered
to avoid adverse effects.
Biography
Sarah Martin has completed her BSc in Physiology and Pharmacology at the University of Saskatchewan. Her project aimed to study the effects of oral arginine
supplements on male Sprague-Dawley and Zucker Diabetic Fatty rats. She is pursuing her MSc and is excited to start the Post Degree Nursing program next
spring with the final goal of becoming a nurse practitioner.
Sarah Martin, Clin Pharmacol Biopharm, Volume 08